Xizang Haisco Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd (002653) has an Asset Resilience Ratio of 1.70% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002653 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Xizang Haisco Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. See 002653 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Xizang Haisco Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Xizang Haisco Pharmaceutical Group Co Lt.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥130.00 Million | 1.7% |
| Total Liquid Assets | CN¥130.00 Million | 1.70% |
Asset Resilience Insights
- Limited Liquidity: Xizang Haisco Pharmaceutical Group Co Ltd maintains only 1.70% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xizang Haisco Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Xizang Haisco Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Xizang Haisco Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.21% | CN¥150.13 Million ≈ $21.97 Million |
CN¥6.80 Billion ≈ $994.82 Million |
-0.20pp |
| 2023-12-31 | 2.41% | CN¥160.06 Million ≈ $23.42 Million |
CN¥6.65 Billion ≈ $973.53 Million |
+5.77pp |
| 2022-12-31 | -3.36% | CN¥-203.16 Million ≈ $-29.73 Million |
CN¥6.05 Billion ≈ $884.95 Million |
+0.30pp |
| 2021-12-31 | -3.66% | CN¥-183.34 Million ≈ $-26.83 Million |
CN¥5.01 Billion ≈ $732.43 Million |
-11.07pp |
| 2020-12-31 | 7.41% | CN¥370.32 Million ≈ $54.19 Million |
CN¥5.00 Billion ≈ $731.65 Million |
+0.84pp |
| 2019-12-31 | 6.56% | CN¥330.47 Million ≈ $48.36 Million |
CN¥5.04 Billion ≈ $736.82 Million |
-2.16pp |
| 2018-12-31 | 8.73% | CN¥380.99 Million ≈ $55.75 Million |
CN¥4.37 Billion ≈ $638.86 Million |
+6.90pp |
| 2017-12-31 | 1.83% | CN¥75.10 Million ≈ $10.99 Million |
CN¥4.11 Billion ≈ $601.25 Million |
+1.69pp |
| 2016-12-31 | 0.13% | CN¥5.00 Million ≈ $731.66K |
CN¥3.74 Billion ≈ $547.80 Million |
+0.24pp |
| 2015-12-31 | -0.11% | CN¥-3.45 Million ≈ $-504.87K |
CN¥3.23 Billion ≈ $472.29 Million |
-35.76pp |
| 2014-12-31 | 35.65% | CN¥1.02 Billion ≈ $149.99 Million |
CN¥2.87 Billion ≈ $420.69 Million |
+22.22pp |
| 2013-12-31 | 13.43% | CN¥330.00 Million ≈ $48.29 Million |
CN¥2.46 Billion ≈ $359.56 Million |
+13.48pp |
| 2012-12-31 | -0.05% | CN¥-977.11K ≈ $-142.98K |
CN¥1.95 Billion ≈ $284.80 Million |
-- |
| 2008-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥353.69 Million ≈ $51.76 Million |
-- |
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research c… Read more